Pfizer Inc. FY 2025 10-K, explained in plain English
Key financials — as reported
| Total revenue | $62.6B |
| Gross margin | 74.3% |
| Operating income | — not reported |
| Net income | $7.8B |
| Diluted EPS | $1.36 |
| Cash & equivalents | $1.1B |
| Total assets | $208.2B |
| Long-term debt | $61.6B |
Key takeaway
Pfizer reported 2025 total revenue of $62.6 billion but net income dropped sharply to $7.8 billion, partly due to a $4.9 billion asset impairment charge.
🔒 4 more takeaways in the full analysis
Beneath the surface
Cash and equivalents of just $1.14 billion, plus $9.18 billion in current available-for-sale debt securities, total roughly $10.3 billion against $61.6 billion long-term debt plus $3.15 billion current debt, leaving a substantial net debt position of over $54 billion.
🔒 4 more insights a headline reader would miss
This is the free preview. The full analysis explains every line item above and includes 8 more findings — plus insider trades, activist stakes, and 8-K events for PFE.
Read the full analysis free Free account · 5 full analyses included · no card required